ArticleClinical journal of gastroenterology2022
Dramatic disappearance of hyperglycemia and abnormal neurologic symptoms after resection of duodenal gastrointestinal stromal tumor.
Article in Clinical journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal stromal tumor (GIST) is a common mesenchymal neoplasm of the gastrointestinal (GI) tract. Paraneoplastic syndromes of GISTs are rare; in particular, GIST-induced hyperglycemia has not been reported. A 67-year-old woman presented with recurrent alteration of consciousness and uncontrolled hyperglycemia. Computed tomography scans showed a huge hypervascular mass, located medial to the superior mesenteric vessels. Endoscopic ultrasonography (EUS) with fine-needle aspiration (FNA) showed spindle cell tumors, diagnosed as borderline resectable duodenal GIST. There was partial response after 6 months of Imatinib treatment. En-bloc resection was performed via the laparotomy. The histology confirmed a high-risk GIST at the third part of the duodenum. The abnormal symptoms then dramatically disappeared. She has remained recurrence free for 22 months. Uncontrolled hyperglycemia and abnormal neurological conditions are rare in GIST; however, a large hypervascular GIST could cause paraneoplastic syndromes or consume the products from an adjacent structure, requiring complete tumor resection. This case adds the knowledge of an extremely rare presentation of GIST and, moreover, extremely rare cause of uncontrolled hyperglycemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.